Monday 12 May, 2025 01:21 AM
Site map | Locate Us | Login
   Reliance Power reports turnaround Q4 numbers    GRSE Q4 PAT tanks 60% YoY to Rs 363 cr; declares dividend of Rs 5.40/sh    Bank of India Q4 PAT climbs 82% YoY to Rs 2,626 cr; declares dividend of Rs 4.05/sh    Thermax Q4 PAT jumps 8% YoY to Rs 206 cr; declares dividend of Rs 14/sh    Dr Reddys Lab Q4 PAT rises 22% YoY    Swiggy net loss widens to Rs 1081 crore in Q4FY25    Japan's SMBC to acquire 20% stake in Yes Bank    K.P.R. Mill rallies as Q4 PAT inches up 1% QoQ to Rs 205 crore    Kirloskar Ferrous rises as Q4 PAT spurts 417% YoY to Rs 92 cr    Lloyd Ent slips after Q4 PAT drops 55% YoY to Rs 9 cr    Alkyl Amines Q4 PAT rises 20% YoY to Rs 46 cr; declares dividend of Rs 10/sh    Ideaforge Tech reports dismal Q4 outcome    Grindwell Norton Ltd leads losers in 'A' group    Intellect Design Arena gains after Q4 PAT spurts 85% YoY to Rs 135 cr    R Systems Intl gains after Q1 PAT rises 40% YoY 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Lupin gets USFDA nod for Eslicarbazepine Acetate tablets
08-May-25   08:26 Hrs IST

The company is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity.

Eslicarbazepine Acetate Tablets, 200 mg, 400 mg, 600 mg, and 800 mg are bioequivalent to Aptiom Tablets, 200 mg, 400 mg, 600 mg, and 800 mg, of Sumitomo Pharma America, Inc., and indicated for the treatment of partial-onset seizures in patients 4 years of age and older.

As per IQVIA MAT March 2025, Eslicarbazepine Acetate Tablets had estimated annual sales of $395 million in the U.S.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company's consolidated net profit jumped 39.5% to Rs 855.16 crore in Q3 FY25 as compared with Rs 613.12 crore in Q4 FY24. Net sales increased 10.6% YoY to Rs 5618.56 crore during the quarter ended 31st March 2025.

The scrip advanced 1.08% to end at Rs 2,070.95 on Wednesday, 7 May 2025.

Powered by Capital Market - Live News
   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Investor Charter | Annual Return | Account Closure | RE-KYC | Disclaimer | Feed Back | Privacy Policy | Policies & Procedures | |Rights & Obligations-English| Rights & Obligations-தமிழ் | Anti Money Laundering Policy | E-Voting | CSR | Voluntary Freezing / Blocking | Policy GTC Hit Count : 40783266
Useful Links : NSE | BSE | MCX | NSDL | CDSL | SEBI | RBI | ATTENTION INVESTOR| SMART ODR
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd